#United States #Washington, D.C. #diagnostics #Co-Diagnostics #Next Generation Dx

Co-Diagnostics to Host Booth at Next Generation Dx Summit

Co-Diagnostics, Inc. (Nasdaq: CODX), a leader in molecular diagnostics, is excited to announce its participation in the 17th Annual Next Generation Dx Summit. Scheduled to take place both virtually and in person from August 18-20, 2025, at the Capital Hilton in Washington, D.C., this premier event will serve as a vital platform for professionals across the globe to converge and share insights into advances in diagnostic technology.

As one of the distinguished exhibitors, Co-Diagnostics invites all attendees to visit Booth #12. Here, visitors can explore the innovative Co-Dx Logix Smart® suite, an advanced clinical laboratory solution crafted to empower healthcare providers with precise and rapid diagnostic capabilities. Additionally, the company will preview its forthcoming Co-Dx PCR diagnostics platform, which, accompanied by a range of upper respiratory, tuberculosis, and HPV tests, aims to enhance diagnostics remarkably in 2025.

The Next Generation Dx Summit, hosted by the Cambridge Healthtech Institute, is recognized as the nexus for international thought leaders focused on diagnostic advancements. This year’s summit promises insightful discussions about point-of-care testing, decentralized testing, infectious disease management, liquid biopsy applications, and companion diagnostics. These topics are pivotal as the diagnostics landscape rapidly evolves towards enhancing the standard of care across diverse medical contexts.

With emphasis on revolutionary trends and practices, attendees can expect a rich learning experience filled with opportunities to network with industry peers. Co-Diagnostics’ participation is significantly bolstered by a grant from the World Trade Center Utah, which focuses on aiding Utah-based businesses in expanding their international reach. This support is crucial not only for engaging in vital discussions during the summit but also for fostering partnerships that could drive future innovations.

It is worth noting that the Co-Dx PCR platform, which includes the groundbreaking Co-Dx PCR Home™, Co-Dx PCR Pro™, and a comprehensive mobile application designed for analyzing tests, is currently under review by the FDA and other regulatory bodies and is not yet available for purchase.

Co-Diagnostics, Inc. is dedicated to advancing molecular diagnostics by developing, manufacturing, and marketing innovative technologies tailored for the detection and analysis of nucleic acid molecules like DNA and RNA. The company prides itself on utilizing proprietary technology to design highly specific tests aimed not only at infectious diseases but also at identifying genetic markers for a variety of applications.

For registration details and further information about the summit, interested parties can visit Next Generation Dx Summit. Don't miss out on this opportunity to connect with industry leaders and discover how Co-Diagnostics is shaping the future of molecular diagnostics.